Table 1.
Basic clinical characteristics in each treatment group
| Dara-CyBorD (n = 147) | CyBorD (n = 214) | P value | |
|---|---|---|---|
| Age, median (range), y | 65 (23-82) | 64.5 (35-89) | .64 |
| Sex, male, n (%) | 95 (64.6) | 134 (62.6) | .73 |
| Light chain isotype, n (%) | .07 | ||
| λ | 119 (81.0) | 155 (72.4) | |
| κ | 28 (19.0) | 58 (27.1) | |
| Baseline dFLC | |||
| Median (IQR), mg/dL | 24.7 (10.1-55.9) | 27.5 (9.9-69.9) | .74 |
| <5 mg/dL, n (%) | 18 (12.2) | 23 (10.7) | |
| <2 mg/dL, n (%) | 9 (6.1) | 10 (4.6) | |
| BMPC infiltration, median (IQR), % | 10.5 (7.0-20.0) | 10 (5.7-20.0) | .26 |
| Baseline NT-pro BNP, median (IQR), pg/mL | 1326 (261.0-4670) | 2084 (611.8-4841) | .23 |
| Baseline proteinuria, median (IQR), mg/24 h | 1926 (241.0-5090) | 1948 (335.0-5684) | .64 |
| Involved organs, n (%) | |||
| Heart | 94 (63.9) | 152 (71.0) | .16 |
| Kidney | 84 (57.1) | 117 (54.6) | .66 |
| Liver | 13 (8.8) | 35 (16.3) | .04 |
| Gastrointestinal tract | 23 (15.6) | 35 (16.3) | .88 |
| Peripheral nerve | 8 (5.4) | 16 (7.4) | .52 |
| Autonomic nervous system | 13 (8.8) | 24 (11.2) | .48 |
| Others | 21 (14.2) | 23 (10.7) | .32 |
| Mayo 2004 cardiac stage with European modification, n (%) | |||
| I | 37 (25.1) | 29 (13.5) | .005 |
| II | 43 (29.2) | 77 (35.9) | .21 |
| IIIA | 39 (26.5) | 64 (29.9) | .55 |
| IIIB | 16 (10.8) | 32 (14.9) | .27 |
| Missing | 12 (8.1) | 12 (5.6) | |
| Renal stage, n (%) | |||
| I | 32 (38.1) | 28 (23.9) | .04 |
| II | 29 (34.5) | 52 (44.4) | .18 |
| III | 20 (23.8) | 30 (25.6) | .86 |
| Missing | 3 (3.6) | 7 (5.9) |
IQR, interquartile range. Bold indicates statistical significance at p<0.05.